In use product safety assessment report for infliximab biosimilars - update

This assessment summarises practical in-use safety considerations associated with the use of infliximab products. The updated document now includes Remsima subcutaneous and Zessly® in addition to Flixabi®, Inflectra® and Remsima® intravenous.

Specialist Pharmacy Service